Background: In Vietnam, there are increase rate of patients with acute leukemia including acute myelogenous leukemia. The clinical, gender, age as well as morphological characteristics of cells have prognostic significance about response to treatment and survival time of patients. Objectives: (1) To describe the distribution of acute myelogenous leukemia types by FAB standard in 'National Institute of Hematology and Blood Transfusion. (2) To describe the clinical characteristics of patients with acute myelogenous leukemia. Subjects and methods: The study included 67 patients diagnosed acute myelogenous leukemia by FAB standard without chemotherapy in 'National Institute of Hematology and Blood Transfusion. Results and conclusions: The median age: 35.55 \xb1 13.46, sex: 53% male, 47% female. Ratio of M0, M1, M2, M3, M4, M5, M6, M7 was 1, 10, 19, 18, 30, 13, 6, 1 %, respectively. 100% of these patients presented with anemia, 57 % with hemorrage, 46 % with fever. Lymphadenopathy was presented in 61 %, hepatomegaly was presented in 27% and spleenomegaly was presented in 9%. 53% of the patients had more bleeding was M3. Lymphadenopathy, hepatospleenomegaly had most frequently seen in the patients of M4 and M5 type. \r\n", u'\r\n', u'
Leukemia ; Myeloid ; Acute/ immunology ; Hematology

Dendritic cells can be derived from leukemia cells and normal precursor cells in the patients with acute myeloid leukemia (AML). Dendritic cells may capture leukemia antigen in bone marrow or lymph nodes, and present leukemia common antigen to stimulate proliferation of specific CD8(+) T cells, playing anti-leukemia effect. Dendritic cells for clinical and experimental use are transformed from leukemia cells and peripheral blood mononuclear cells and loaded in vitro with leukemia -specific or tumor common antigen, play a therapeutic role after reinfusion. This article reviews dendritic cells in the immunotherapy of AML.
Dendritic Cells ; immunology ; Humans ; Immunotherapy ; Leukemia, Myeloid, Acute ; immunology ; therapy

Since the last decade, new insights into inflammatory processes have become possible by investigating the pattern of cytokines in acute and chronic sinus diseases. This review aims to update and discuss the findings of in vitro and in vivo studies concerning the role of cytokines in sinusitis and nasal polyposis. The proinflammatory cytokines interleukin-1beta, interleukin-6 and the neutrophil-chemoattractant interleukin-8 may play a major role in acute sinusitis, as shown in viral and allergic rhinitis. In chronic sinusitis interleukin-3 dominates the cytokine profiles, giving support to a variety of inflammatory cells. Interleukin-5 is a key protein in the pathogenesis of nasal polyposis. Activation and survival of eosinophils in nasal polyps are thought to be regulated by interleukin-5. Further investigation of cytokine expression patterns in inflammatory sinus diseases will lead to a better understanding of their pathogenesis and to a development of new therapeutic modality.
Acute Disease ; Chronic Disease ; Cytokines/immunology* ; Human ; Polyps/immunology ; Rhinitis/immunology* ; Sinusitis/immunology*

Since the last decade, new insights into inflammatory processes have become possible by investigating the pattern of cytokines in acute and chronic sinus diseases. This review aims to update and discuss the findings of in vitro and in vivo studies concerning the role of cytokines in sinusitis and nasal polyposis. The proinflammatory cytokines interleukin-1beta, interleukin-6 and the neutrophil-chemoattractant interleukin-8 may play a major role in acute sinusitis, as shown in viral and allergic rhinitis. In chronic sinusitis interleukin-3 dominates the cytokine profiles, giving support to a variety of inflammatory cells. Interleukin-5 is a key protein in the pathogenesis of nasal polyposis. Activation and survival of eosinophils in nasal polyps are thought to be regulated by interleukin-5. Further investigation of cytokine expression patterns in inflammatory sinus diseases will lead to a better understanding of their pathogenesis and to a development of new therapeutic modality.
Acute Disease ; Chronic Disease ; Cytokines/immunology* ; Human ; Polyps/immunology ; Rhinitis/immunology* ; Sinusitis/immunology*

Acute Disease ; Humans ; Leukemia, Myeloid, Acute ; immunology ; metabolism ; Male ; Middle Aged ; Myocardial Infarction ; immunology ; metabolism

Antibodies, Viral ; blood ; Humans ; SARS Virus ; immunology ; Severe Acute Respiratory Syndrome ; immunology ; T-Lymphocytes, Cytotoxic ; immunology

Angiopoietin2( ANGPT2 ) plays an important role in tumor angiopoiesis. ANGPT2 antagonises ANGPT1 resulting in an effect on the stability of blood vessels, which promotes tumor growth, invasion, proliferation as well as relating to tumor vascular density. A lot of researches published papers about anti-ANGPT2 for the treatment of tumor, and have made some progresses. In this review, the role of ANGPT2 in the pathogenesis of acute myelogenous leukemia (AML), including its effects on proliferation of leukemia cells, bone marrow angiopoiesis, tumor invasion and metastasis are briefly summarised in order to provide the basis for targeted ANGPT2 in treatment of AML.
Angiopoietin-1 ; immunology ; Antibodies ; immunology ; Bone Marrow ; Humans ; Leukemia, Myeloid, Acute ; immunology ; Neoplasm Invasiveness ; Neoplasm Metastasis

Acute hemorrhagic edema of infancy is an unusual form of leukocytoclastic vasculitis occuring in children from the age 4 months to 2 years. The etiology remains unknown. Numerous studies, however, suggest acute hemorrhagic edema of infancy as an immune-mediated vasculitis in response to a variety of antigenic stimuli. We report a case of an acute hemorrhagic edema of infancy; 11-month-old boy with a history of fever for 3 days and a history of purpuric rash on the extremities, trunk, buttock and oral mucosa for 2 days.
Acute Disease ; Biopsy ; Edema/immunology/*pathology ; Exanthema/immunology/pathology ; Hemorrhage/immunology/*pathology ; Human ; Infant ; Male ; Vasculitis, Hypersensitivity/immunology/*pathology

To evaluate the sensitivity and specificity analysis of the lineage related antibodies in acute leukemia immunophenotyping by flow cytometry (FCM), immunophenotyping in 184 patients with acute leukemia was performed by FCM analysis. The results showed that in the lineage-related antibodies of acute myelocytic leukemia (AML), the sensitivity of CD13 and CD33 was higher (95.5% and 91.2%, respectively), the specificity of them was deficient (72.5% and 62.2%, respectively); the sensitivity of MPO was low (69.1%), but the specificity was high (100%); the sensitivity and specificity of CD117 were high (88.2% and 100%, respectively); the sensitivity of CD14 and CD15 was low (18.4% and 27.2%, respectively); the specificity of CD14 with monocytes was high. As the lineage-related antibodies of B-lineage ALL were concerned, CD19 showed high sensitivity and low specificity (100% vs 83.4%); the sensitivity and specificity of CD79a (96.4% vs 100%) and CD22 (100% vs 100%) were high; the sensitivity and specificity of CD10 (53.6% vs 82.5%) and CD20 (70.4% vs 87.5%) were low. In T-lineage ALL, the specificity of CD3 was high (97.5%), but the sensitivity was below the mark (80.0%); the sensitivity of CD7 was high (100%), but the specificity was low (77.9%); while the sensitivity and specificity of CD5, CD2 and CD1a were all deficient. In conclusion, the sensitivity and specificity analysis of the lineage-related antibodies in acute leukemia immunophenotyping are coincident with St Jude immunophenotyping project. It seems only that CD117 is superior to MPO in defining AML, but the sensitivity and specificity analysis of CD22 and CD79 are similar in defining B-lineage ALL, therefore, anyone of them may be selected as your need.
Acute Disease ; Adolescent ; Adult ; Aged ; Antibodies, Monoclonal ; immunology ; Antibodies, Neoplasm ; immunology ; CD79 Antigens ; analysis ; immunology ; Child ; Child, Preschool ; Female ; Flow Cytometry ; methods ; Humans ; Immunophenotyping ; methods ; Leukemia ; classification ; immunology ; Leukemia, Erythroblastic, Acute ; immunology ; Leukemia, Monocytic, Acute ; immunology ; Leukemia, Myeloid ; immunology ; Leukemia, Myeloid, Acute ; immunology ; Leukemia, Promyelocytic, Acute ; immunology ; Male ; Middle Aged ; Proto-Oncogene Proteins c-kit ; analysis ; immunology ; Reproducibility of Results ; Sialic Acid Binding Ig-like Lectin 2 ; analysis ; immunology

The purpose of this review is to provide an overview of the effect of (lymph)angiogenic cytokines on hematopoietic cells involved in acute myeloid leukemia (AML). Like angiogenesis, lymphangiogenesis occurs in pathophysiological conditions but not in healthy adults. AML is closely associated with the vasculature system, and the interplay between lymphangiogenic cytokines maintains leukemic blast survival in the bone marrow (BM). Once AML is induced, proangiogenic cytokines function as angiogenic or lymphangiogenic factors and affect hematopoietic cells, including BM-derived immune cells. Simultaneously, the representative cytokines, VEGFs and their receptors are expressed on AML blasts in vascular and osteoblast niches in both the BM and the peripheral circulation. After exposure to (lymph)angiogenic cytokines in leukemogenesis and infiltration, immune cell phenotypes and functions are affected. These dynamic behaviors in the BM reflect the clinical features of AML. In this review, we note the importance of lymphangiogenic factors and their receptors in hematopoietic cells in AML. Understanding the functional characterization of (lymph)angiogenic factors in the BM niche in AML will also be helpful in interrupting the engraftment of leukemic stem cells and for enhancing immune cell function by modulating the tumor microenvironment.
Animals ; Cytokines/*immunology ; Hematopoietic Stem Cells/immunology/*pathology ; Humans ; Immunity, Cellular ; Leukemia, Myeloid, Acute/immunology/*physiopathology ; *Lymphangiogenesis ; Lymphatic Vessels/immunology/*physiopathology ; Vascular Endothelial Growth Factor A/immunology